Daunorubicin and adriamycin are anthracycline drugs used in the chemotherapy of acute myelogenous leukaemia and other cancers (Crowther et al., 1973; Staquet et al., 1975) . Their use is limited by their tendency to induce cardiac failure (Middleman, Luce and Frei, 1971; Malpas and Bodley Scott 1969) , but there have been a number of reports (Lefrak et al., 1973; Kimura, 1972) to suggest that these cardiotoxic effects may be attenuated by the prior administration of digoxin. The mechanism of this reported attenuation is unknown, but it has been proposed (Fiorentino et al., 1974) that perhaps the cardiac glycoside digoxin competes with the anthracycline glycosides for the same binding sites. We have examined this possibility in the rat but have found no evidence to suggest that prior treatment with digoxin can prevent adriamycin and daunorubicin binding to rat cardiac muscle.
We used adult male Wistar rats, each weighing approximately 250 g. Sets of 4 rats were injected intravenously with up to 500 ,ug digoxin, or alternatively by 3 daily injections of 500 ,ug digoxin. At various times after injection the rats were injected with various amounts of daunorubicin; up to 20 mg per rat. At 0, 4, 8 and 24 h after daunorubicin injection a rat was killed, its heart removed, washed in ice-cold isotonic saline, minced, homogenized in 5 ml ice-cold saline and the bound daunorubicin and its metabolites extracted according to the method of Huffman, Benjamin and Bachur (1973 Table. Similar experiments have been performed with drugs other than daunorubicin. We have used adriamycin, propranolol (4 mg/ 250 g rat), ICRF 159 (100 mg/rat), and digitoxin (500 pg/rat) instead of digoxin. Propranolol binds to beta-adrenergic receptors and might therefore compete with daunorubicin if it were to bind to the beta receptors on the heart. ICRF 159 has been reported to afford some prophylactic protection against daunorubicin (Herman et al., 1972) 
